BERKELEY, Calif.--(BUSINESS WIRE)--Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells. The Phase 2 trial is one of several planned proof-of-concept trials to be initiated with PLX3397 in 2011.
